Applying machine learning to international drug monitoring: classifying cannabis resin collected in Europe using cannabinoid concentrations.

Journal: European archives of psychiatry and clinical neuroscience
PMID:

Abstract

In Europe, concentrations of ∆-tetrahydrocannabinol (THC) in cannabis resin (also known as hash) have risen markedly in the past decade, potentially increasing risks of mental health disorders. Current approaches to international drug monitoring cannot distinguish between different types of cannabis resin which may have contrasting health effects due to THC and cannabidiol (CBD) content. Here, we compared concentrations of THC and CBD in different types of cannabis resin collected in Europe (either Moroccan-type, or Dutch-type). We then tested the ability of machine learning algorithms to classify the type of cannabis resin (either Moroccan-type, or Dutch-type) using routinely collected monitoring data on THC and CBD. Finally, we applied the optimal algorithm to new samples collected in countries where the type of cannabis resin was unknown, the UK and Denmark. Results showed that overall, Dutch-type samples had higher THC (Hedges' g = 2.39) and lower CBD (Hedges' g = 0.81) than Moroccan-type samples. A Support Vector Machine algorithm achieved classification accuracy exceeding 95%, with little variation in this estimate, good interpretability, and plausibility. It made contrasting predictions about the type of cannabis resin collected in the UK (94% Moroccan-type; 6% Dutch-type) and Denmark (36% Moroccan-type; 64% Dutch-type). In conclusion, we provide proof-of-concept evidence for the potential of machine learning to inform international drug monitoring. Our findings should not be interpreted as objective confirmatory evidence but suggest that Dutch-type cannabis resin has higher THC concentrations than Moroccan-type cannabis resin, which may contribute to variation in drug markets and health outcomes for people who use cannabis in Europe.

Authors

  • Tom P Freeman
    Addiction and Mental Health Group (AIM), Department of Psychology, University of Bath, Bath, UK. t.p.freeman@bath.ac.uk.
  • Edward Beeching
    Hugging Face, Paris, France.
  • Sam Craft
    Addiction and Mental Health Group (AIM), Department of Psychology, University of Bath, Bath, UK.
  • Marta Di Forti
    MRC Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK.
  • Giampietro Frison
    Laboratory of Clinical and Forensic Toxicology, DMPO Department, AULSS 3, Venice, Italy.
  • Christian Lindholst
    Section for Toxicology and Drug Analysis, Department of Forensic Medicine, Aarhus University, Aarhus, Denmark.
  • Pieter E Oomen
    Trimbos Institute, The Netherlands Institute of Mental Health and Addiction, Utrecht, Netherlands.
  • David Potter
    , Canterbury, UK.
  • Sander Rigter
    Trimbos Institute, The Netherlands Institute of Mental Health and Addiction, Utrecht, Netherlands.
  • Kristine Rømer Thomsen
    Centre for Alcohol and Drug Research, Department of Psychology and Behavioural Sciences, Aarhus University, Aarhus, Denmark.
  • Luca Zamengo
    Laboratory of Clinical and Forensic Toxicology, DMPO Department, AULSS 3, Venice, Italy.
  • Andrew Cunningham
    European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Lisbon, Portugal.
  • Teodora Groshkova
    European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Lisbon, Portugal.
  • Roumen Sedefov
    European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Lisbon, Portugal.